The NF-κB pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance

Leukemia

Volumn 20, Issue 1, 2006, Pages 61-67

  Cilloni, Daniela ^a   Messa, F ^a   Arruga, F ^a   Defilippi, I ^a   Morotti, A ^a   Messa, E ^a   Carturan, S ^a   Giugliano, E ^a   Pautasso, M ^a   Bracco, E ^b   Rosso, V ^a   Sen, A ^c   Martinelli, G ^d   Baccarani, M ^d   Saglio, G ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

CML; Imatinib; NF B; PS1145

Indexed keywords

BCR ABL PROTEIN; I KAPPA B KINASE INHIBITOR; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PS 1145; UNCLASSIFIED DRUG; 6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; ANTINEOPLASTIC AGENT; DNA; FUSED HETEROCYCLIC RINGS; I KAPPA B KINASE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA BINDING; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING; BINDING SITE; BONE MARROW CELL; CELL CULTURE; CELL STRAIN K 562; CELL SURVIVAL; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; BLOTTING, WESTERN; BONE MARROW CELLS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; COMBINED MODALITY THERAPY; DNA; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; I-KAPPA B KINASE; K562 CELLS; LEUKEMIA, MYELOID, CHRONIC; NF-KAPPA B; PIPERAZINES; PYRIDINES; PYRIMIDINES; TUMOR STEM CELL ASSAY;

EID: 33644968734     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403998     Document Type: Article

References (34)

1. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
2. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:. 994-1004.
3. Kantarjian HM, Cortes JE, O'Brien S, Giles F, Garcia-Manero G, Faderl S et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: High incidence of early complete and major cytogenetic responses. Blood 2003; 101: 97-100.
4. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rio's MB et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002; 99: 3547-3553.
5. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
6. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanism of resistance to Imatinib in Philadelphia-chromosome-positive leukemias. Lancet Oncol 2003; 4: 75-85.
7. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
8. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276-283.
9. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002; 109: 81-96.
10. Lin A, Karin M. NF-κB in cancer: A merked target. Semin Cancer Biol 2003; 13: 107-114.
11. Garg A, Aggarwal BB. Nuclear transcription factor-kB as a target for cancer drug development. Leukemia 2002; 16: 1053-1068.
12. Turco MC, Romano MF, Petrella A, Bisogni R, Tassone P, Venuta S. NF-κB/ Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia 2003; 18: 1-7.
13. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301-2307.
14. Bueso-Ramos CE, Rocha FC, Shishodia S, Medeiros LJ, Kantarjian HM, Vadhan-Raj S et al. Expression of constitutively active nuclear-kappa B ReIA transcription factor in blasts of acute myeloid leukemia. Hum Pathol 2004; 35: 246-253.
15. Baumgartner B, Weber M, Quirling M, Fischer C, Page S, Adam M et al. Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts. Leukemia 2002; 16: 2062-2071.
16. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000; 3: 399-402.
17. Bailly JD, Skladanowski A, Bettaieb A, Mansat V, Larsen AK, Laurent G. Natural resistance of acute myeloid leukemia cell lines to mitoxantrone is associated with lack of apoptosis. Leukemia 1997; 9: 1523-1532.
18. Panwalkar A, Verstovsek S, Giles F. Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies. Cancer 2004; 15: 1578-1589.
19. Umezawa K, Chaicharoenpong C. Molecular design and biological activities of NF-kappaB inhibitors. Mol Cells 2002; 14: 163-167.
20. Karin M; Ben-Neriah Y. Phosphorilation meets ubiquitination: The control of NF-κB activity. Annu Rev Immunol 2000; 18: 621-663.
21. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol 2002; 3: 221-227.
22. Senftleben U, Karin M. The IKK/NF-κB pathway. Crit Care Med 2002; 30: 18-26.
23. Hayashi T, Hideshima T, Anderson KC. Novel therapies for multiple myeloma. Br J Haematol 2003; 120: 10-17.
24. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 16639-16647.
25. Cilloni D, Carlo-Stella C, Falzetti F, Sammarelli G, Regazzi E, Colla S et al. Limited engraftment capacity of bone marrow-derived mesenchymal cells following T cell depleted hematopoietic stem cell transplantation. Blood 2000; 96: 3637-3643.
26. Aradhya S, Nelson DL. NF-κB signaling and human disease. Curr Opin Genet Dev 2000; 11: 300-306.
27. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18: 6853-6866.
28. Li ZW, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M et al. The IKK beta subunit of I kappa B kinase B kinase (IKK) is essential for nuclear factor kappa B activatation and prevention of apoptosis. J Exp Med 1999; 189: 1839-1845.
29. Zandi E, Chen Y, Karin M. Direct phosphorilation of IKappaB by IKKalpha and IKK beta: Discrimination between free and NF-κB bound substrate. Science 1998; 281: 1360-1363.
30. Delhase M, Hayakawa M, Chen Y, Karin M. Positive and negative regulation of I kappa B kinase activity through IKK beta subunit phosphorylation. Science 1999; 284: 309-313.
31. Kavai H, Nie L, Yuan ZM. Inactivation of NF-κB dependent cell survival, a novel mechanisn for the proapoptotic function of c-ABL. Mol Cell Biol 2002; 22: 6079-6088.
32. Shaul Y. c-ABL:aCtivation and nuclear targets. Cell Death Differ 2000; 7: 10-16.
33. Pendergast AM. The Abl family kinases: Mechanism of regulation and signaling. Adv Cancer Res 2002; 85: 51-100.
34. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS. A requirement for NF-κB activation in BCR-ABL mediated transformation. Genes Dev 1998; 12: 968-981.